Autologous stromal vascular fraction cells: A tool for facilitating tolerance in rheumatic disease

Ichim, Thomas E.; Harman, Robert J.; Min, Wei‐Ping; Minev, Boris; Solano, Fabio; Rodríguez, Jorge Paz; Alexandrescu, Doru T; Necochea-Campion, Rosalia de; Hu, Xiang; Marleau, Annette M.; Riordan, Neil H

doi:10.1016/j.cellimm.2010.04.002

Cited by 32 publications

(24 citation statements)

References 203 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reprogramming memory may suggest incomplete reprogramming of iPSCs, while if pPiPSCs could retain the properties of original cells that could be beneficial in clinical practice or basic research, they may have useful applications. ADSCs possess the capacity of multipotency (Oswald et al 2004, Lindroos et al 2011, high activity of secretion (Spaggiari et al 2009, Nguyen et al 2010, homing (Lamfers et al 2009), and immune modification (Yanez et al 2006), and have been widely used in cell replacement therapy (CRT) and clinical research (Trivedi et al 2008, Ichim et al 2010. We questioned as to whether pPiPSCs retained these favorable characteristics after reprogramming.…”

Section: Discussionmentioning

confidence: 99%

“…Owing to their low immunogenicity and immunosuppression in vivo and in vitro, ADSCs can be applied in healing immunodeficiency diseases such as graft-vs-host diseases (Yanez et al 2006), diabetes (Trivedi et al 2008), and rheumatoid arthritis (Ichim et al 2010). When antigens enter the body, their major histocompatibility complex (MHC) is the first to be recognized and provides the first signal of the immune response.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Characterization of porcine partially reprogrammed iPSCs from adipose-derived stem cells

Wei¹,

Li²,

Zhang³

et al. 2015

Reproduction

View full text Add to dashboard Cite

Partially reprogrammed induced pluripotent stem cells (PiPSCs) have great potential for investigating reprogramming mechanisms and represent an alternative potential material for making genetically modified animals and regenerative medicine. To date, PiPSCs have scarcely been reported in detail when compared with mice and humans. In this study, we obtained PiPSCs from porcine adipose-derived stem cells (pADSCs) by ectopic expression of human transcription factors (OCT4, SOX2, c-MYC, and KLF4) in feeder-free condition. The morphology and proliferation activity of porcine PiPSCs (pPiPSCs) were similar to those of porcine fully reprogrammed iPSCs (pFiPSCs); furthermore, pPiPSCs expressed higher levels of the typical surface molecules (CD29) found in pADSCs. However, pPiPSCs were negative for key proteins (NANOG) connected with stemness and possessed lower differentiation ability in vivo and in vitro. When differentiationinhibiting factors were withdrawn, pPiPSCs-derived cells (pPiPSC-DCs) showed similar features to pADSCs in many aspects, including proliferation, differentiation, and immunosuppression. When both types of cells were used to produce cloned embryos, we found that the blastocyst formation rate of 19DC (one of the pPiPSC-DC cell lines)-derived cloned embryos was obviously higher than that of others. The total cell number of 19DC-derived blastocysts was significantly higher than the 30DC (one pFiPSC-DC cell line)-derived blastocysts. In all, through limited differentiation ability, the proliferation activity of pPiPSCs is similar to that of pFiPSCs, and pPiPSCs can retain several of the features of pADSCs, which are beneficial to cell therapy. Furthermore, the differentiation of pPiPSCs is more favorable for producing high-quality reconstructed embryos. Free Chinese abstract: A Chinese translation of this abstract is freely available at

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Characterization of porcine partially reprogrammed iPSCs from adipose-derived stem cells

Wei¹,

Li²,

Zhang³

et al. 2015

Reproduction

View full text Add to dashboard Cite

show abstract

“…If it is assumed the circulating half-life of the human cytokines administered to the CAIA mice was minutes to hours [24], this reduction of the clinical score occurred 6 days after the human cytokines were cleared from the circulation. One of the mechanisms of action of MSCs is their ability to induce peripheral T cell tolerance by suppressing T cell proliferation and inducing T regulatory cell production [32,34]. The ability to induce T cell tolerance is an important therapeutic strategy for the effective treatment of autoimmune disorders.…”

Section: Svf Adipocyte Co-culture Secretions: a Promising Therapeuticmentioning

confidence: 99%

“…There is evidence that MSCs secrete cytokines in an environment or injury specific manner, with TGF- and IL-10 being important for inducing tolerance in autoimmune conditions such as RA [35,36]. As discussed by Ichim et al, (2010) the SVF contains a variety of cell types including T regulatory cells and high levels of MSCs [34]. Therefore, in this study, the SVF adipocyte co-culture and SVF secretion mixtures are likely to contain cytokines produced from both MSCs and T regulatory cells that are involved in inducing T cell tolerance.…”

Section: Svf Adipocyte Co-culture Secretions: a Promising Therapeuticmentioning

confidence: 99%

“…This may explain the improvement in the therapeutic effect observed 4 days after the administration of the SVF adipocyte co-culture secretions. If SVF cell therapy was used as the therapeutic it is anticipated that the MSCs would induce T cell tolerance over a longer post-treatment period [34,37] Although it is likely that the effects observed with conditioned media will be similar to SVF cell therapy, there will be some differences. After the infusion of a mixed population of cells, such as SVF with adipocytes the subsequent therapeutic effect appears to be separated into two related phases.…”

Section: Svf Adipocyte Co-culture Secretions: a Promising Therapeuticmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of a mouse model of collagen antibody-induced arthritis with human adipose-derived secretions

Blaber¹,

Webster²,

Breen³

et al. 2013

OJRM

View full text Add to dashboard Cite

The use of adipose-derived cells as a treatment for a variety of diseases is becoming increasingly common. These therapies include the use of cultured mesenchymal stem cells (MSCs) and freshly isolated stromal vascular fraction (SVF) alone, or in conjunction with other cells such as adipocytes. There is a substantial amount of literature published on the therapeutic properties of MSCs and their secretions as the main driver of their therapeutic effect. However, there is little data available on the therapeutic potential of secretions from SVF, either with or without adipocytes. We investigated the ability of secretions from human adipose SVF alone and the SVF co-cultured with adipocytes as a proxy for cell therapy, to ameliorate an inflammatory disorder. This ethics approved study involved the treatment of collagen antibody-induced arthritis (CAIA) in mice with secretions from SVF, SVF co-cultured with adipocytes, or a vehicle control via both intravenous (IV) and intramuscular (IM) routes. Treatment outcome was assessed by paw volume, ankle size and clinical arthritis score measurements. Serum samples were obtained following euthanasia and analysed for a panel of 32 mouse cytokines and growth factors. The dose and timing regime used for the IM administration of both human secretion mixtures did not significantly ameliorate arthritis in this model. The IV administration of SVF adipocyte co-culture secretions reduced the paw volume, and significantly reduced the ankle size and clinical arthritis score when compared to the IV vehicle control mice. This was a superior therapeutic effect than treatment with SVF secretions. Furthermore, treatment with SVF adipocyte coculture secretions resulted in a significant reduction in serum levels of key cytokines, IL-2 and VEGF, involved in the pathogenesis of rheumatoid arthritis. Therefore, the SVF cocultured with adipocytes is an attractive therapeutic for inflammatory conditions.

show abstract

Adipose-Derived Stem Cells: Characterization and Application in Urology

Lin

Lue

2011

Adipose Stem Cells and Regenerative Medicine

View full text Add to dashboard Cite

Autologous stromal vascular fraction cells: A tool for facilitating tolerance in rheumatic disease

Cited by 32 publications

References 203 publications

Characterization of porcine partially reprogrammed iPSCs from adipose-derived stem cells

Characterization of porcine partially reprogrammed iPSCs from adipose-derived stem cells

Treatment of a mouse model of collagen antibody-induced arthritis with human adipose-derived secretions

Adipose-Derived Stem Cells: Characterization and Application in Urology

Contact Info

Product

Resources

About